Intech Investment Management LLC Invests $133,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Intech Investment Management LLC acquired a new position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,149 shares of the company’s stock, valued at approximately $133,000.

A number of other large investors also recently modified their holdings of YMAB. Price T Rowe Associates Inc. MD raised its holdings in shares of Y-mAbs Therapeutics by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Y-mAbs Therapeutics by 8.0% in the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock valued at $1,461,000 after buying an additional 8,974 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in shares of Y-mAbs Therapeutics by 4.2% in the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock valued at $1,084,000 after buying an additional 3,589 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Y-mAbs Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 82,202 shares of the company’s stock valued at $993,000 after buying an additional 2,760 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after buying an additional 65,732 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

YMAB has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Morgan Stanley lowered their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. Canaccord Genuity Group upgraded Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, Oppenheimer began coverage on Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Y-mAbs Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.89.

Y-mAbs Therapeutics Stock Up 2.3 %

Shares of NASDAQ YMAB opened at $10.54 on Friday. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $6.09 and a fifty-two week high of $20.90. The business has a 50 day moving average price of $13.24 and a two-hundred day moving average price of $12.76. The firm has a market cap of $472.09 million, a PE ratio of -19.52 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the previous year, the business posted ($0.18) EPS. On average, analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.64 earnings per share for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 30.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.50% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.